DBVT HealthcareBeta data

DBV Technologies S.A.

$10.11+11.71%

Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: France
Market cap: 635.4M USD
Enterprise value: 425.1M USD
Full-time employees: 170

Overall health

Strength: growing faster than most peersgrowing faster than peers
Strength: lower risk than most peers: less debt relative to equitylower risk: less debt vs equity
Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Ranks #836 of 1,157 healthcare companies (bottom 28%)

See how it ranks against its peers

Worth knowing

Stock-based pay is a large cost. Stock pay was 96% of revenue in 2025.
DBV Technologies paid employees $5M in stock in 2025, 96% of its $6M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, DBV Technologies looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Growing fast, still losing money. Revenue grew faster than 87% of peers, at an operating loss, from a small base ($5.0M of revenue over 12 months).
Revenue grew faster than 87% of peers, but the business runs at an operating loss (margin -3532%).

StockQuotient Score

39/ 100

Oct 5 39 → Nov 4 39

Fundamentals: Yahoo Finance, not primary filings

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-34.6%

Yahoo Finance · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-41.1%

Yahoo Finance · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-26.9%

Yahoo Finance · trailing 12 months · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield26.8%

Yahoo FinanceReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

70/100

Moderate

2/3 inputs reported · Partial data

Since last quarter: ▼ Weaker

12-month revenue fell 12.2%

Why

Stronger than most peers on:

▲ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0976 · MAD: 0.2991

3-year revenue growth-1.4%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score -0.86Sector median: 0.0584 · MAD: 0.0840

Revenue growth33.1%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 2.77Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

1/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Operating margin
▼ ROA
▼ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-3531.7%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -71.87Sector median: 0.0706 · MAD: 0.1217

Return on assets-78.8%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -11.22Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-9219.1%

Yahoo Finance · trailing 12 monthsOutlier capped at sector 5th/95th percentile33% base weight · Z-score -16.87Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin100.0%

Yahoo Finance · trailing 12 monthsOutlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-142.7%

Yahoo Finance · trailing 12 monthsOutlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

2/3 inputs reported · Partial data

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Debt / equity
▲ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

BetaUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.6250 · MAD: 0.3380

Current ratio3.72×

Yahoo FinanceReported value33% base weight · Z-score 0.82Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.05×

Yahoo FinanceReported value33% base weight · Z-score 0.85Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about DBV Technologies

Is DBV Technologies getting weaker?: Its latest SEC filing (Jul 16, 2026) got weaker in some ways: 12-month revenue fell 12.2%. Its overall score is unchanged at 39/100 since Oct 28, 2026.
How is DBV Technologies valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -34.6% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -34.6% vs peers 1.5% (weaker than 100% of peers).
Is DBV Technologies growing?: Yes, faster than most of its peers. Growth scores 70/100 against 1,393 healthcare peers. Revenue growth 33.1% vs a peer median of 6.1% (stronger than 87% of peers).Revenue growth 33.1% vs peers 6.1% (stronger than 87% of peers). 3-year revenue growth -1.4% vs a peer median of 5.8% (weaker than 75% of peers).3-year revenue growth -1.4% vs peers 5.8% (weaker than 75% of peers).
How profitable is DBV Technologies?: Less profitable than most of its peers. Profitability scores 1/100 against 1,393 healthcare peers. Operating margin -3531.7% vs a peer median of 7.1% (weaker than 100% of peers).Operating margin -3531.7% vs peers 7.1% (weaker than 100% of peers).
How risky is DBV Technologies?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.05× vs a peer median of 0.22× (stronger than 76% of peers).Debt / equity 0.05× vs peers 0.22× (stronger than 76% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Jul 16, 2026 · compared with the quarter ended Mar 31, 2026

Got weaker

12-month revenue fell 12.2%

Worth watching: DBV Technologies is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Revenue (12 months)	5.7M USD	5.0M USD	−12.2%
Net income (12 months)	−167.4M USD	−175.9M USD	+5.1%
Operating margin	-2935.1%	-3531.7%	−596.6 pts
Free cash flow (12 months)	−151.5M USD	−170.6M USD	+12.6%
Cash	229.2M USD	174.9M USD	−23.7%
Shares outstanding	296.0M	296.1M	+0.0%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Operating margin	-1727.6%	-1994.9%	-486.0%	-2808.7%	-2609.2%	▲ 199 pts
Net margin	-1713.5%	1987.5%	462.3%	-2744.4%	-2607.3%	▲ 137 pts
Return on assets (ROA)	-66.7%	39.1%	39.7%	-173.5%	-62.9%	▲ 111 pts
Return on equity (ROE)	-98.5%	49.5%	51.9%	-416.0%	-87.1%	▲ 329 pts
Free cash flow margin	-1912.3%	-1164.7%	-510.7%	-2573.2%	-2159.6%	▲ 414 pts
Current ratio	3.64×	7.56×	4.26×	1.43×	3.67×	▲ 157%
Quick ratio	—	—	—	—	—	—
Debt to equity	0.01×	—	—	—	—	—

DBVT price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: growing faster than most peersgrowing faster than peers

Strength: lower risk than most peers: less debt relative to equitylower risk: less debt vs equity

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Ranks #836 of 1,157 healthcare companies (bottom 28%)

See how it ranks against its peers

Worth knowing

Stock-based pay is a large cost. Stock pay was 96% of revenue in 2025.

DBV Technologies paid employees $5M in stock in 2025, 96% of its $6M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, DBV Technologies looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Growing fast, still losing money. Revenue grew faster than 87% of peers, at an operating loss, from a small base ($5.0M of revenue over 12 months).

Revenue grew faster than 87% of peers, but the business runs at an operating loss (margin -3532%).

Questions investors ask about DBV Technologies

Is DBV Technologies getting weaker?

Its latest SEC filing (Jul 16, 2026) got weaker in some ways: 12-month revenue fell 12.2%. Its overall score is unchanged at 39/100 since Oct 28, 2026.

How is DBV Technologies valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -34.6% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -34.6% vs peers 1.5% (weaker than 100% of peers).

Is DBV Technologies growing?

Yes, faster than most of its peers. Growth scores 70/100 against 1,393 healthcare peers. Revenue growth 33.1% vs a peer median of 6.1% (stronger than 87% of peers).Revenue growth 33.1% vs peers 6.1% (stronger than 87% of peers). 3-year revenue growth -1.4% vs a peer median of 5.8% (weaker than 75% of peers).3-year revenue growth -1.4% vs peers 5.8% (weaker than 75% of peers).

How profitable is DBV Technologies?

Less profitable than most of its peers. Profitability scores 1/100 against 1,393 healthcare peers. Operating margin -3531.7% vs a peer median of 7.1% (weaker than 100% of peers).Operating margin -3531.7% vs peers 7.1% (weaker than 100% of peers).

How risky is DBV Technologies?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.05× vs a peer median of 0.22× (stronger than 76% of peers).Debt / equity 0.05× vs peers 0.22× (stronger than 76% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

5.7M USD

5.0M USD

−12.2%

Net income (12 months)

−167.4M USD

−175.9M USD

+5.1%

Operating margin

-2935.1%

-3531.7%

−596.6 pts

Free cash flow (12 months)

−151.5M USD

−170.6M USD

+12.6%

Cash

229.2M USD

174.9M USD

−23.7%

Shares outstanding

296.0M

296.1M

+0.0%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Operating margin

-1727.6%

-1994.9%

-486.0%

-2808.7%

-2609.2%

▲ 199 pts

Net margin

-1713.5%

1987.5%

462.3%

-2744.4%

-2607.3%

▲ 137 pts

Return on assets (ROA)

-66.7%

39.1%

39.7%

-173.5%

-62.9%

▲ 111 pts

Return on equity (ROE)

-98.5%

49.5%

51.9%

-416.0%

-87.1%

▲ 329 pts

Free cash flow margin

-1912.3%

-1164.7%

-510.7%

-2573.2%

-2159.6%

▲ 414 pts

Current ratio

3.64×

7.56×

4.26×

1.43×

3.67×

▲ 157%

Quick ratio

—

Debt to equity

0.01×

—